AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

GILD · NASDAQ · Drug Manufacturers - General

Gilead Sciences (GILD)

Develops HIV antivirals, liver-disease medicines, and oncology therapies including CAR-T treatments.

$152.11

After-hours close−0.56 (−0.37%)

At close$152.67(+1.40%)

Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
Business WireSep 17
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks Investment ResearchSep 17
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
Zacks Investment ResearchSep 16
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances
MarketBeatSep 15
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking AlphaSep 15
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
GuruFocusSep 15
Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean
ReutersSep 15
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
Business WireSep 15
Bank of America Corp DE Sells 1,329,871 Shares of Gilead Sciences, Inc. $GILD
Defense WorldSep 15
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Zacks Investment ResearchSep 14
Baird Financial Group Inc. Grows Holdings in Gilead Sciences, Inc. $GILD
Defense WorldSep 11Ownership
Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Seeking AlphaSep 10Earnings
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth
MarketBeatSep 10
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Seeking AlphaSep 10Earnings
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode
MarketBeatSep 10Clinical
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
Zacks Investment ResearchSep 8Market move
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
GuruFocusSep 8Operations
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
Business WireSep 8Operations
California State Teachers Retirement System Has $30.47 Billion Stake in Gilead Sciences, Inc. $GILD
Defense WorldSep 8Ownership
Compass Financial Management LLC Invests $671,000 in Gilead Sciences, Inc. $GILD
Defense WorldSep 7Ownership